Chris Varma Email Address

Co-Founder, Chairman and Chief Executive Officer

Blueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets.

Chris joined MPM in 2017 as an Entrepreneur-in-Residence. An experienced entrepreneur and investor in the life sciences industry, he co-founded Blueprint Medicines (Nasdaq: BPMC), an oncology therapeutics company, and served as its President and Chief Executive Officer. Along with his scientific co-founders, whom he recruited, Chris envisioned Blueprint’s unique platform, recruited the leadership and scientific teams, raised $40M in a Series A financing and oversaw the building of the scientific platform and therapeutic pipeline that is now in clinical testing. Most recently, Chris co-founded and served as President and Chief Executive Officer of Vision Medicines, an orphan ophthalmology company.Previously at Third Rock Ventures as an Entrepreneur-in-Residence, Chris co-founded Warp Drive Bio, a natural products company. Prior to Third Rock Ventures, he was a Partner at Flagship Ventures focusing on life science investments such as Tetraphase Pharmaceuticals (Nasdaq: TTPH) and running Selventa, Inc. (f.k.a. Genstruct, Inc.), a Flagship portfolio company, where he led a rapid turnaround that achieved profitability. Before joining Flagship, he oversaw efforts spanning business development, strategy, and sales and marketing at Novartis AG.Chris has a Ph.D. in Biomedical Sciences from the Harvard-MIT Program in Health Sciences & Technology, an M.S. in Management from Stanford University, and an M.S. and B.S. in Computer Science from Stanford University. Chris serves as a member of the Harvard Medical School (HMS) Therapeutics Advisory Council and the HMS Discovery Council, as a leadership board member of The McGovern Institute for Brain Research at MIT, and as a member of the board of directors of the Global Oncology Initiative.